Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 6, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tejas Savant Downgraded (AKYA) to Hold and Decreased Target to $3 on, Aug 6th, 2024
Tejas Savant of Morgan Stanley, Downgraded "Akoya Biosciences, Inc." (AKYA) to Hold and Decreased Target from $4 to $3 on, Aug 6th, 2024.
Tejas has made no other calls on AKYA in the last 4 months.
There is 1 other peer that has a rating on AKYA. Out of the 1 peers that are also analyzing AKYA, 0 agree with Tejas's Rating of Hold.
This is the rating of the analyst that currently disagrees with Tejas
- Kyle Mikson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $6 on, Tuesday, May 14th, 2024
